Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD

114.08  +0.27 (+0.24%)

After market: 114.08 0 (0%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to SRPT. SRPT was compared to 572 industry peers in the Biotechnology industry. SRPT has only an average score on both its financial health and profitability. SRPT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

SRPT had positive earnings in the past year.
In the past year SRPT has reported a negative cash flow from operations.
In the past 5 years SRPT always reported negative net income.
In the past 5 years SRPT reported 4 times negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200M -400M -600M

1.2 Ratios

The Return On Assets of SRPT (3.38%) is better than 93.98% of its industry peers.
Looking at the Return On Equity, with a value of 9.98%, SRPT belongs to the top of the industry, outperforming 95.40% of the companies in the same industry.
SRPT has a Return On Invested Capital of 2.21%. This is amongst the best in the industry. SRPT outperforms 93.98% of its industry peers.
Industry RankSector Rank
ROA 3.38%
ROE 9.98%
ROIC 2.21%
ROA(3y)-17.4%
ROA(5y)-22%
ROE(3y)-96.74%
ROE(5y)-90.07%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

Looking at the Profit Margin, with a value of 7.43%, SRPT belongs to the top of the industry, outperforming 94.16% of the companies in the same industry.
The Operating Margin of SRPT (4.94%) is better than 94.34% of its industry peers.
SRPT has a Gross Margin of 85.92%. This is amongst the best in the industry. SRPT outperforms 89.03% of its industry peers.
In the last couple of years the Gross Margin of SRPT has remained more or less at the same level.
Industry RankSector Rank
OM 4.94%
PM (TTM) 7.43%
GM 85.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.13%
GM growth 5Y-0.17%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SRPT is destroying value.
The number of shares outstanding for SRPT has been increased compared to 1 year ago.
Compared to 5 years ago, SRPT has more shares outstanding
Compared to 1 year ago, SRPT has an improved debt to assets ratio.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

2.2 Solvency

SRPT has an Altman-Z score of 2.24. This is not the best score and indicates that SRPT is in the grey zone with still only limited risk for bankruptcy at the moment.
SRPT has a better Altman-Z score (2.24) than 72.21% of its industry peers.
A Debt/Equity ratio of 0.93 indicates that SRPT is somewhat dependend on debt financing.
SRPT has a Debt to Equity ratio of 0.93. This is in the lower half of the industry: SRPT underperforms 78.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF N/A
Altman-Z 2.24
ROIC/WACC0.22
WACC10.16%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 3.84 indicates that SRPT has no problem at all paying its short term obligations.
The Current ratio of SRPT (3.84) is comparable to the rest of the industry.
SRPT has a Quick Ratio of 3.03. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
SRPT has a Quick ratio of 3.03. This is in the lower half of the industry: SRPT underperforms 63.01% of its industry peers.
Industry RankSector Rank
Current Ratio 3.84
Quick Ratio 3.03
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

More info and screens

8

3. Growth

3.1 Past

SRPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 115.96%, which is quite impressive.
The Revenue has grown by 48.46% in the past year. This is a very strong growth!
The Revenue has been growing by 32.80% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)115.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%173.91%
Revenue 1Y (TTM)48.46%
Revenue growth 3Y32.04%
Revenue growth 5Y32.8%
Sales Q2Q%40.79%

3.2 Future

Based on estimates for the next years, SRPT will show a very strong growth in Earnings Per Share. The EPS will grow by 37.85% on average per year.
Based on estimates for the next years, SRPT will show a very strong growth in Revenue. The Revenue will grow by 29.35% on average per year.
EPS Next Y143.28%
EPS Next 2Y96.48%
EPS Next 3Y66.26%
EPS Next 5Y37.85%
Revenue Next Year51.52%
Revenue Next 2Y60.37%
Revenue Next 3Y47.08%
Revenue Next 5Y29.35%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 15

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 91.26, which means the current valuation is very expensive for SRPT.
Compared to the rest of the industry, the Price/Earnings ratio of SRPT indicates a rather cheap valuation: SRPT is cheaper than 93.27% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of SRPT to the average of the S&P500 Index (28.47), we can say SRPT is valued expensively.
A Price/Forward Earnings ratio of 10.02 indicates a reasonable valuation of SRPT.
SRPT's Price/Forward Earnings ratio is rather cheap when compared to the industry. SRPT is cheaper than 97.70% of the companies in the same industry.
SRPT is valuated cheaply when we compare the Price/Forward Earnings ratio to 92.74, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 91.26
Fwd PE 10.02
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SRPT is valued cheaply inside the industry as 93.81% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 82.93
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

SRPT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SRPT's earnings are expected to grow with 66.26% in the coming years.
PEG (NY)0.64
PEG (5Y)N/A
EPS Next 2Y96.48%
EPS Next 3Y66.26%

More info and screens

0

5. Dividend

5.1 Amount

SRPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (2/4/2025, 8:09:07 PM)

After market: 114.08 0 (0%)

114.08

+0.27 (+0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners95.88%
Inst Owner Change-0.09%
Ins Owners4.35%
Ins Owner Change0.12%
Market Cap10.90B
Analysts84.83
Price Target187.88 (64.69%)
Short Float %5.51%
Short Ratio5.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)761%
Min EPS beat(2)348.76%
Max EPS beat(2)1173.24%
EPS beat(4)4
Avg EPS beat(4)1281.93%
Min EPS beat(4)348.76%
Max EPS beat(4)3019.73%
EPS beat(8)7
Avg EPS beat(8)621.33%
EPS beat(12)8
Avg EPS beat(12)394.44%
EPS beat(16)9
Avg EPS beat(16)293.96%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-9.09%
Max Revenue beat(2)11.9%
Revenue beat(4)3
Avg Revenue beat(4)2.7%
Min Revenue beat(4)-9.09%
Max Revenue beat(4)11.9%
Revenue beat(8)6
Avg Revenue beat(8)3.53%
Revenue beat(12)8
Avg Revenue beat(12)2.31%
Revenue beat(16)10
Avg Revenue beat(16)1.97%
PT rev (1m)-0.49%
PT rev (3m)-3.59%
EPS NQ rev (1m)26.42%
EPS NQ rev (3m)-12.66%
EPS NY rev (1m)16.65%
EPS NY rev (3m)57.28%
Revenue NQ rev (1m)3.13%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)1.18%
Revenue NY rev (3m)6.34%
Valuation
Industry RankSector Rank
PE 91.26
Fwd PE 10.02
P/S 6.64
P/FCF N/A
P/OCF N/A
P/B 8.92
P/tB 9.13
EV/EBITDA 82.93
EPS(TTM)1.25
EY1.1%
EPS(NY)11.39
Fwd EY9.98%
FCF(TTM)-5.03
FCFYN/A
OCF(TTM)-3.69
OCFYN/A
SpS17.17
BVpS12.78
TBVpS12.49
PEG (NY)0.64
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.38%
ROE 9.98%
ROCE 2.79%
ROIC 2.21%
ROICexc 3.76%
ROICexgc 3.82%
OM 4.94%
PM (TTM) 7.43%
GM 85.92%
FCFM N/A
ROA(3y)-17.4%
ROA(5y)-22%
ROE(3y)-96.74%
ROE(5y)-90.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.13%
GM growth 5Y-0.17%
F-Score4
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF N/A
Debt/EBITDA 9.49
Cap/Depr 330.83%
Cap/Sales 7.8%
Interest Coverage 5.07
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.84
Quick Ratio 3.03
Altman-Z 2.24
F-Score4
WACC10.16%
ROIC/WACC0.22
Cap/Depr(3y)129.44%
Cap/Depr(5y)182.5%
Cap/Sales(3y)5.55%
Cap/Sales(5y)9.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)115.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%173.91%
EPS Next Y143.28%
EPS Next 2Y96.48%
EPS Next 3Y66.26%
EPS Next 5Y37.85%
Revenue 1Y (TTM)48.46%
Revenue growth 3Y32.04%
Revenue growth 5Y32.8%
Sales Q2Q%40.79%
Revenue Next Year51.52%
Revenue Next 2Y60.37%
Revenue Next 3Y47.08%
Revenue Next 5Y29.35%
EBIT growth 1Y120.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year186.86%
EBIT Next 3Y112.35%
EBIT Next 5YN/A
FCF growth 1Y-66.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.35%
OCF growth 3YN/A
OCF growth 5YN/A